Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes

Open access

Abstract

OBJECTIVE—The physiology of counterregulatory responses during hypoglycemia in intensively treated type 2 diabetic subjects is largely unknown. Therefore, the specific aims of the study tested the hypothesis that 1) 6 months of intensive therapy to lower A1C <7.0% would blunt autonomic nervous system (ANS) responses to hypoglycemia, and 2) antecedent hypoglycemia will result in counterregulatory failure during subsequent hypoglycemia in patients with suboptimal and good glycemic control. RESEARCH DESIGN AND METHODS—Fifteen type 2 diabetic patients (8 men/7 women) underwent 6-month combination therapy of metformin, glipizide XL, and acarbose to lower A1C to 6.7% and 2-day repeated hypoglycemic clamp studies before and after intensive therapy. A control group of eight nondiabetic subjects participated in a single 2-day repeated hypoglycemic clamp study. RESULTS—Six-month therapy reduced A1C from 10.2 ± 0.5 to 6.7 ± 0.3%. Rates of hypoglycemia increased to 3.2 episodes per patient/month by study end. Hypoglycemia (3.3 ± 0.1 mmol/l) and insulinemia (1,722 ± 198 pmol/l) were similar during all clamp studies. Intensive therapy reduced (P < 0.05) ANS and metabolic counterregulatory responses during hypoglycemia. Antecedent hypoglycemia produced widespread blunting (P < 0.05) of neuroendocrine, ANS, and metabolic counterregulatory responses during subsequent hypoglycemia before and after intensive therapy in type 2 diabetic patients and in nondiabetic control subjects. CONCLUSIONS—Intensive oral combination therapy and antecedent hypoglycemia both blunt physiological defenses against subsequent hypoglycemia in type 2 diabetes. Prior hypoglycemia of only 3.3 ± 0.1 mmol/l can result in counterregulatory failure in type 2 diabetic patients with suboptimal control and can further impair physiological defenses against hypoglycemia in intensively treated type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db08-1230

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Plasma glucose and insulin levels during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. Type 2 diabetic patients are studied before (pre) and after (post) 6 months of intensive triple oral combination anti-diabetes therapy. •, Day 1 pre; ▪, day 2 pre; ▴, day 1 post; ▿, day 2 post; ♦, day 1 controls; ○, day 2 controls.
FIG. 1. Plasma glucose and insulin levels during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. Type 2 diabetic patients are studied before (pre) and after (post) 6 months of intensive triple oral combination anti-diabetes therapy. •, Day 1 pre; ▪, day 2 pre; ▴, day 1 post; ▿, day 2 post; ♦, day 1 controls; ○, day 2 controls.CC BY-NC-ND · PubMed Central
FIG. 2. Plasma epinephrine, glucagon, and cortisol levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma epinephrine, glucagon, and cortisol levels are significantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects and patients with type 2 diabetes both before (pre) and after (post) 6-month intensive triple oral combination anti-diabetes therapy. †Plasma epinephrine levels are significantly reduced (P < 0.05) after 6-month intensive triple oral combination anti-diabetes therapy. ‡Plasma cortisol levels are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetic patients before intensive therapy.
FIG. 2. Plasma epinephrine, glucagon, and cortisol levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma epinephrine, glucagon, and cortisol levels are significantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects and patients with type 2 diabetes both before (pre) and after (post) 6-month intensive triple oral combination anti-diabetes therapy. †Plasma epinephrine levels are significantly reduced (P < 0.05) after 6-month intensive triple oral combination anti-diabetes therapy. ‡Plasma cortisol levels are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetic patients before intensive therapy.CC BY-NC-ND · PubMed Central
FIG. 3. Plasma growth hormone and pancreatic polypeptide levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma growth hormone and pancreatic polypeptide levels are significantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects.
FIG. 3. Plasma growth hormone and pancreatic polypeptide levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma growth hormone and pancreatic polypeptide levels are significantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects.CC BY-NC-ND · PubMed Central
FIG. 4. Blood glycerol, lactate, and plasma NEFA levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Blood glycerol, lactate, and plasma NEFA levels are significantly reduced (P < 0.05) in healthy control subjects and patients with type 2 diabetes both before (pre) and after (post) 6-month intensive triple oral combination anti-diabetes therapy. †Blood glycerol, lactate, and plasma NEFA levels are reduced (P < 0.05) after 6-month intensive therapy in type 2 diabetes. ‡Blood glycerol, lactate, and plasma NEFAs are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetes before intensive therapy.
FIG. 4. Blood glycerol, lactate, and plasma NEFA levels in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Blood glycerol, lactate, and plasma NEFA levels are significantly reduced (P < 0.05) in healthy control subjects and patients with type 2 diabetes both before (pre) and after (post) 6-month intensive triple oral combination anti-diabetes therapy. †Blood glycerol, lactate, and plasma NEFA levels are reduced (P < 0.05) after 6-month intensive therapy in type 2 diabetes. ‡Blood glycerol, lactate, and plasma NEFAs are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetes before intensive therapy.CC BY-NC-ND · PubMed Central
FIG. 5. Δ responses from baseline in MSNA and hypoglycemic symptom scores in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Δ MSNA and symptom responses are significantly reduced (P < 0.05) in type 2 diabetic patients and healthy control subjects. †Δ MSNA and symptom responses are significantly reduced (P < 0.05) in type 2 diabetes after 6-month intensive triple oral combination anti-diabetic therapy. ‡Δ MSNA and symptom responses are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetes before intensive therapy (PRE).
FIG. 5. Δ responses from baseline in MSNA and hypoglycemic symptom scores in the final 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Δ MSNA and symptom responses are significantly reduced (P < 0.05) in type 2 diabetic patients and healthy control subjects. †Δ MSNA and symptom responses are significantly reduced (P < 0.05) in type 2 diabetes after 6-month intensive triple oral combination anti-diabetic therapy. ‡Δ MSNA and symptom responses are significantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetes before intensive therapy (PRE).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 75

Metadata

Authors
Davis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., & Tate, D. B.
Affiliations
Vanderbilt University (US)
Venue
Diabetes
Published
2009-03-01
Volume
58
Issue
3
Pages
701-709
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2137066860
Cited by
74
References
39
Citations by year
2026: 2 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 4 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 4 · 2014: 4 · 2013: 11 · 2012: 4
FWCI
5.06
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Vanderbilt University
  • Deutsches Krebsforschungszentrum
  • National Institutes of Health (5p60dk020593-31, DK-020593)
  • National Heart, Lung, and Blood Institute (P01HL056693)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, R01DK069803)
  • National Center for Research Resources (M01RR000095, MO1-RR-000095)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
type 2 diabetes, hypoglycemia, counterregulatory response, tight glycemic control, autonomic nervous system, hypoglycemic clamp, insulin levels, metformin, glipizide, acarbose, glycemic variability
MeSH terms
Autonomic Nervous System, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Fatty Acids, Nonesterified, Glucose, Glycerol, Glycated Hemoglobin, Homeostasis, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Lactates, Neurosecretory Systems, Glucose Clamp Technique

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db08-1230
The paper
Davis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., & Tate, D. B. (2009). Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db08-1230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.